HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burkhoff, D. Articles by Lansing, A. M. Search for Related Content PubMed PubMed Citation Articles by Burkhoff, D. Articles by Lansing, A. M.

CLINICAL STUDIES

Factors correlating with risk of mortality after transmyocardial revascularization

Daniel Burkhoff, MD, PhD^*, Margaret N. Wesley, PhD, Jon R. Resar, MD, FACC and Allan M. Lansing, MD

^* Department of Medicine, Columbia University, New York, New York, USA
Information Management Services, Inc, Silver Spring, Maryland, USA
Department of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA
Audubon Heart Center, Louisville, Kentucky, USA

Manuscript received March 6, 1998; revised manuscript received February 9, 1999, accepted March 19, 1999.

Reprint requests and correspondence: Dr. Daniel Burkhoff, Department of Medicine, Columbia University, 630 West 168^th Street, New York, New York 10032
db59{at}columbia.edu

	Abstract

Top Abstract Physiologic considerations Methods Results Discussion References

 
OBJECTIVES

The purpose of this study was to determine factors correlating with the risk of postoperative mortality after transmyocardial laser revascularization (TMR).

BACKGROUND

Clinical studies have indicated that TMR reduces angina by an average of two classes in patients with medically refractory symptoms not treatable by coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty. Factors which correlate with mortality after TMR, however, have not been extensively investigated.

METHODS

One hundred thirty-two patients with severe angina underwent TMR as sole therapy with a CO₂ laser. Age, gender, ejection fraction, prior CABG, unstable angina and the severity of coronary artery disease (graded on the basis of a newly proposed Anatomic Myocardial Perfusion index, AMP) were each determined. Each vascular territory (left anterior descending artery [LAD] left circumflex artery and posterior descending artery [PDA]) was graded as either having (AMP = 1) or not having (AMP = 0) blood flow through an unobstructed major vessel in the territory. Univariate and multivariate analysis determined which factors correlated with mortality.

RESULTS

Patients with at least one AMP = 1 vascular territory (overall AMP = 1) had a 5% (4/82) postoperative mortality rate (POM), compared with 25% (12/49) with overall AMP 0 (p = 0.002). Left anterior descending artery AMP (p = 0.03) and previous CABG (p = 0.04) each correlated with the risk of POM. However, multivariate analysis indicated that no factor improved the correlation obtained with overall AMP by itself. With regard to overall mortality (Kaplan-Meier curves), univariate analysis also revealed correlations with overall AMP (p < 0.001), LAD AMP (p = 0.005), previous CABG (p = 0.003) and PDA AMP (p = 0.05) each individually correlated with mortality. Multivariate analysis indicated that overall AMP = 1, female gender and previous CABG together correlated best with lower postoperative mortality.

CONCLUSIONS

Patients with good blood flow to at least one region of the heart through a native artery or a patent vascular graft have a markedly reduced risk of perioperative and longer term mortality.

Abbreviations and Acronyms   AMP = Anatomic Myocardial Perfusion index   CABG = coronary artery bypass graft   EF = ejection fraction   LAD = left anterior descending artery   TMR = transmyocardial revascularization

Despite having now accrued significant clinical experience with this procedure (with reports of up to 4,000 procedures having been performed worldwide), much less attention has focused on understanding factors that may predict which patients benefit most and which are at increased risk of morbidity and mortality from this procedure. Perioperative mortality rates between 3% and 20% have been reported (2–5,7); the reason for this wide range is unknown. Patient eligibility criteria have varied significantly among various ongoing and completed studies and among different investigators, but a generally accepted set of criteria has not emerged. The purpose of this study is to investigate factors that correlate with the risk of mortality after TMR.

	Physiologic considerations

Top Abstract Physiologic considerations Methods Results Discussion References

 
It was originally proposed that myocardial perfusion could be achieved by the creation of transmyocardial channels which communicate with the left ventricular cavity (1), thus mimicking the physiology of blood flow in reptile hearts (10). However, results of physiologic and anatomic studies in experimental animal models have suggested that blood does not flow through these channels (11–17). This is particularly the case for the acute setting, where it has been demonstrated that TMR channels do not protect myocardial viability in the face of severe acute ischemia (18–20). If applicable to the clinical setting, these findings would suggest that patients undergoing TMR may not derive any perfusion benefit in the days after the procedure. It is therefore possible that patients who are particularly susceptible to ischemia may be at increased risk of perioperative morbidity and mortality because of the stress associated with surgery and the postoperative recovery period. This, in combination with other physiologic considerations (see Discussion), has led to the hypothesis that patients with severe unbypassed three-vessel (or unbypassed left main) disease who lack any areas of myocardium protected by blood flow through patent vessels are at increased risk of perioperative mortality after TMR.

	Methods

Top Abstract Physiologic considerations Methods Results Discussion References

 
Between February 1994 and October 1996, 132 patients with medically refractory class III and IV angina underwent TMR as sole therapy with a CO₂ laser (The Heart Laser, PLC Systems Inc., Franklin, Massachusetts) at the Audubon Heart Center in Louisville, Kentucky by a single operator (A.M.L.). These subjects took part in an investigation of the safety and efficacy of TMR in which the Audubon Heart Center participated. Each patient provided informed consent after being told of the risks and potential benefits of participating in the study. The protocols under which the studies were conducted were approved by the local ethics committee. The present study is a retrospective analysis of the data collected from those patients.

Demographic and medical data were collected on all 132 patients. A preliminary evaluation of many factors and survey of published reports had indicated that the most relevant factors to examine more closely were age, gender, ejection fraction, the presence of prior bypass surgery, the occurrence of unstable angina in the preoperative period and the severity of coronary artery disease. The severity of coronary vascular disease was graded on the basis of angiographic findings as detailed below.

Review and grading of coronary angiograms.   The original angiograms of 109 of the patients were retrieved and reviewed by one of the cardiologists participating in this study (D.B. or J.R.R.) who was blinded as to whether the patient did or did not die any time during the follow-up period. For those patients whose angiogram could not be retrieved for review, grading of the extent of vascular disease was based on the report of the most recent angiogram; again, this was also done without knowledge of outcome. The severity of coronary artery disease was graded according to what we have termed the "Angiographic Myocardial Perfusion (AMP) score." The intent of the AMP score is to provide a simple system for designating whether there is or is not an unobstructed path for blood flow to and through the major vessel of a specified region of the heart. In the case that such an unobstructed path exists, the region may be considered to be protected, in the sense that it should not be vulnerable to ischemia during times of stress. Inherent to this grading system is the notion that the path for blood flow may be either entirely through the native vasculature or it may include surgically placed conduits. Each of the three major vascular territories (anterior, lateral and inferior) was graded separately according to the following definitions. A region was considered to have an AMP score of "1" if myocardial perfusion was provided through a major vessel in the region, and the path for blood flow (be it through native vessels or through vascular grafts) was not affected by hemodynamically significant stenoses (i.e., no greater than 50% lumenal narrowings). A region was considered to have an AMP score of "0" if myocardial perfusion in the region was only provided through minor vessels or through vessels with hemodynamically significant stenoses (lumenal narrowings 50%). In addition to grading each region individually, an overall AMP score was designated as "1" if there was at least one AMP 1 region on the heart; otherwise the overall AMP score was designated as "0". Guidelines were established to identify "major" vessels in each of the three regions. The left anterior descending artery (LAD) was considered the major vessel for the anterior wall. For the lateral wall, any large caliber marginal branch which reached at least three quarters of the distance from the base to the apex of the heart was considered a major vessel. Similarly, any large caliber posterior descending artery which reached at least three quarters of the distance between the base and the apex of the heart was considered to be a major vessel.

Statistical methods.   Data are presented as mean ± SD. The Fisher exact test was used to identify variables which might be related to perioperative mortality (death within 30 days of surgery). Age, gender, ejection fraction, presence of unstable angina, prior coronary artery bypass graft (CABG) experience, anterior AMP, lateral AMP, inferior AMP and overall AMP were also examined using logistic regression. The log-rank test and Cox regression were used to investigate whether any variables or combination of variables were significant predictors of overall survival. Survival curves were estimated using the Kaplan-Meier procedure (21). Hypotheses were tested against two-sided alternatives, and significance levels were set at 0.05.

To test whether there was a "training effect" (i.e., if mortality decreased as the operator gained experience), surgical date was entered as an additional variable. The results of that analysis showed that surgical date did not impact on survival; this factor will not be discussed further.

There were 132 patients in the data set. Complete data were available for 129 patients. Ejection fraction was not available for two patients and AMP scores were not available for one of the patients. For univariate analyses, all available data on the covariate of interest were used. In the multivariate analysis, only data from patients with complete data were used. The SAS (Cary, North Carolina) software system, Release 6.12, was used for all analyses.

	Results

Top Abstract Physiologic considerations Methods Results Discussion References

 
Patient characteristics are summarized in Table 1. For the group as a whole, mean age was 61.1 ± 11.3 years. Men constituted 82.6% of the patient population, and most patients suffered from class IV angina (95%). Ejection fraction was generally well preserved, averaging 44 ± 12%. Most patients (84%) had a history of at least one bypass surgery in the past. Nearly half of the patients were classified as having unstable angina requiring intravenous heparin and nitroglycerine before the surgery. Most patients (62%) had an overall AMP score of 1, indicating that they had at least one well perfused region of the heart. The anterior region was protected (i.e., anterior AMP score = 1) in 39% of the cases and was the single most frequently well perfused region; this compares with 24% of patients having a protected lateral wall and only 18% of patients having a protected inferior wall. Table 2 provides further detail concerning the type of vessels providing myocardial protection. Among the 132 patients studied, there were a total of 110 protected regions (Tables 1 and 2). Of these, 30 were protected by native vessels, 50 by saphenous veins and 28 (for the anterior region) by internal mammary arteries as further detailed in Table 2. For the anterior region, the mammary artery was the most frequent means of protection, accounting for more than 50% of the cases.

Sixteen of the original 132 patients (12.1%) died within the first 30 days after surgery. An additional 13 deaths occurred between 30 days and 1 year after surgery (total one-year mortality 22%). Eight patients died more than one year after surgery, and the remainder were alive at their last follow-up visit. Patients known to be alive at last follow-up had a median follow-up duration of 12.25 months. Overall 1-year survival is estimated to be 75%. The causes of death are summarized in Table 3. Most deaths were attributable to cardiovascular causes.

View larger version (18K): [in this window] [in a new window]   Figure 1 Kaplan-Meier curves depicting survival in patients having (overall anatomic myocardial perfusion index score [AMP] = 1) or not having (overall AMP = 0) unobstructed blood flow to a major vessel in at least one vascular territory. On the basis of univariate analysis, this factor was the strongest single factor which correlated with the risk of mortality after transmyocardial revascularization (TMR) (p = 0.002).

View larger version (17K): [in this window] [in a new window]   Figure 2 Kaplan-Meier curves depicting survival in patients having (anterior AMP = 1) or not having (anterior AMP = 0) unobstructed blood flow to the left anterior descending artery. On the basis of univariate analysis, this factor also correlated with the risk of mortality after TMR (p = 0.005). Abbreviations as in Figure 1.

View larger version (17K): [in this window] [in a new window]   Figure 3 Kaplan-Meier curves depicting survival in patients having had (coronary artery bypass graft [CABG] = 1) or not having had (CABG = 0) previous coronary bypass surgery. On the basis of univariate analysis, prior CABG predicted a better outcome after transmyocardial revascularization (TMR) (p = 0.003).

View larger version (18K): [in this window] [in a new window]   Figure 4 Kaplan-Meier curves depicting survival in patients having (inferior AMP = 1) or not having (inferior AMP = 0) unobstructed blood flow to the posterior descending artery. On the basis of univariate analysis, this exhibited a statistically significant, though weak correlation with the risk of mortality after TMR (p = 0.05). Abbreviations as in Figure 1.

For patients with at least one protected region, there were a total of only 9 deaths, 4 in the perioperative period and 5 late deaths. Among this small patient group, 6 patients had only 1 protected region and 3 patients had 2 protected regions. Mammary arteries, saphenous veins and native vessels were roughly equally represented in this small patient group. On the basis of this analysis and the analysis provided in Table 2, there is nothing to indicate that mammary arteries were more protective than saphenous veins or native vessels. An additional factor that was tested was whether older graphs provided less protection. This was tested using univariate analysis by entering the difference between the date of last CABG surgery and the TMR date for subjects who had at least one region of protected myocardium. This analysis showed that time since last CABG surgery did not correlate with mortality in this small patient cohort.

	Discussion

Top Abstract Physiologic considerations Methods Results Discussion References

 
The results of this retrospective analysis indicate that patients with unprotected three-vessel disease (overall AMP score = 0) are at high risk of perioperative (25%) and total 1-year (40%) mortality after TMR. Of the three vascular beds, unobstructed blood flow through the LAD (be it entirely through native vessels or through a patent graft to a patent distal vessel) was the most important vessel for predicting survival. Prior CABG afforded a better outcome. Unstable angina tended to yield a worse outcome, but this was not statistically significant.

Most of the patients who are considered candidates for TMR have severe native three-vessel disease. Most patients, however, have had previous bypass surgery and in many instances, one or more of the grafts are still patent. Thus, despite severe native three-vessel disease, one or more of the major vascular territories is frequently protected by a patent graft and in such a case this predicts decreased mortality. Indeed, vascular grafts (either saphenous veins or a mammary artery) were the most frequent (78/108, Table 2) source of myocardial protection. The age of a vascular graft did not correlate with bad outcome, though there were very few patients with protected regions who died. In the present series, 62% (82/132) of the patients fell into the category of having at least one well protected region; over 39% of patients had a well protected LAD system.

Potential mechanisms of benefit.   Several factors may contribute to increased mortality in patients with severe unprotected three-vessel coronary artery disease. First, results of most studies in experimental animal models now suggest that myocardial perfusion is not increased substantially in the acute setting (11,13,14,20,22). Accordingly, it is not expected that patients undergoing TMR surgery would derive an acute perfusion benefit due to the procedure. Yet, patients with severe three-vessel disease are particularly prone to ischemia during periods of physical stress such as would occur during general anesthesia and a thoracotomy, as well as during the postoperative recovery period. In the absence of improved perfusion, these patients would be at increased risk for episodes of myocardial ischemia and possibly even infarction, which appears to be the major cause of mortality seen in the group of patients (Table 2). If this is the primary factor, the risks of this type of therapy might be reduced if the procedure could be performed percutaneously, as is currently being developed (23). It may also be speculated that TMR may disrupt preexistent collateral vessels that developed in the ischemic area, thus interfering with collateral flow in the short run.

The reason for an apparent protective benefit of prior CABG surgery is uncertain. It could reflect a protective effect of previously placed bypass grafts which have remained patent. Alternatively, the poorer outcome in patients without prior bypass may be a reflection of more severe coronary artery disease in subjects who initially present with diffuse unbypassable lesions.

This study has been limited to an analysis of mortality after TMR. We have not addressed other aspects of morbidity because it is not possible to ensure systematic reporting of all adverse events in a retrospective study such as this. Clearly, elucidation of the frequency and factors that predispose to postoperative myocardial infarction, arrhythmias, heart failure, hypotension and other cardiovascular events is an important topic.

In addition, there has been no detailed analysis of the efficacy of TMR, other than to report on the change in angina class in patients who survive the procedure. The patients of the present study were a subset of patients in a larger, multicenter study that had been reported on previously. The authors of those reports suggested that TMR with the CO₂ laser may improve myocardial perfusion (4).

It is also worth specifying that TMR will not alter the AMP score because TMR, a method of indirect revascularization (as compared with CABG, which would be a method of direct revascularization), would not affect the anatomy of the conduit vessels upon which the AMP score is based.

Study limitations.   There are several limitations of this study. First, there is no control group derived from the same patient population which received only medical therapy. Therefore, the mortality of patients with the various risk factors identified in the present study treated medically is unknown. However, results of the Coronary Artery Surgery Study provide some guidelines that help put the results of the present study in perspective (24). In patients with preserved ejection fraction (EF >50%) the total, all-cause one year mortality for patients with three-vessel coronary artery disease treated medically was 2%. This increased to only 3% even in patients with EF <50%. These quoted mortality rates were slightly better than reported in the European Collaborative Study (25) and in the Veterans Administration Study (26), but in no case were these one-year mortality rates in medically treated patients greater than 5%. Although the patients in the present study deemed to be devoid of any protected region (who generally had preserved EF) may have suffered with more severe angina and may have had more severe coronary artery disease, it is unlikely that mortality in such a group followed medically would approach the approximately 20% perioperative mortality plus the additional 20% one-year mortality (total 40% one-year mortality). Furthermore, it could be argued based on clinical grounds that these rates of perioperative and one-year mortality identified in the group of patients without any protected regions would be considered excessive when compared with the types and magnitude of symptomatic improvement being provided by TMR (4).

An additional limitation is that this study is a single-center study. This has the disadvantage that there may be some aspects of patient selection, treatment or care that are unique, and therefore, the results may not extrapolate to all centers performing TMR. The potential advantage of a single-center study is in the uniform procedures for patient selection and treatment. Second, this is a retrospective analysis and it is well known that such results may not apply prospectively. Third, there are a relatively small number of patients and a relatively small number of deaths; therefore the study may be underpowered to detect the importance of all factors examined. For example, there was only a small percentage of women, so the effect of gender on outcome may not be accurate. Average ejection fraction was near normal and there were few patients with ejection fractions less than 30%; therefore, we have not determined the risk of mortality in patients with ejection fractions lower than this value. Accordingly, the results of the present study apply to the group of patients with reasonably well preserved ejection fractions. Fourth, there was a significant number of patients who were lost to follow-up after six months. Therefore, the accuracy of the Kaplan-Meier curves diminishes with time due to the reduction in number of available patients. Fifth, patients of this study were treated with a single laser system (CO₂, The Heart Laser). Because the acute tissue effects of various lasers in clinical use (Ho:YAG, excimer) are different, it is possible that the risks of perioperative mortality may differ with other lasers. Finally, there may be other factors that contribute importantly to the risk of postoperative mortality that have not been considered.

Summary.   In conclusion, when considering TMR for a patient with severe, unprotected coronary disease in all of the three major vascular territories, the potential benefits should be weighed against the possibility of a relatively high mortality. This study was restricted to an analysis of mortality, which is an indisputable, objective end point. It will be equally important to evaluate other end points of benefit (such as exercise tolerance, myocardial perfusion and quality of life) in large numbers of patients so that a realistic estimate of risks and benefits can be provided to patients. Finally, the results of this retrospective study should not necessarily be considered to be generally applicable prospectively, although they may aid with patient selection in some cases.

	Footnotes

 
This study was supported in part by a research grant from CardioGenesis Corp., Sunnyvale, California.

	References

Top Abstract Physiologic considerations Methods Results Discussion References

 

1. Mirhoseini M, Shelgikar S, Cayton MM. New concepts in revascularization of the myocardium. Ann Thorac Surg. 1988;45:415–420[Abstract]
2. Cooley DA, Frazier OH, Kadipasaoglu KA, et al. Transmyocardial laser revascularization: clinical experience with twelve-month follow-up. J Thorac Cardiovasc Surg. 1996;111:791–799[Abstract/Free Full Text]
3. Frazier OH, Cooley DA, Kadipasaoglu KA, et al. Transmyocardial laser revascularization: initial clinical results (abstr). Circulation. 1994;90:I-640
4. Horvath KA, Cohn LH, Cooley DA, et al. Transmyocardial laser revascularization: results of a multicenter trial with transmyocardial laser revascularization used as sole therapy for end-stage coronary artery disease. J Thorac Cardiovasc Surg. 1997;113:645–654[Abstract/Free Full Text]
5. Horvath KA, Mannting F, Cummings N, et al. Transmyocardial laser revascularization: operative techniques and clinical results at two years. J Thorac Cardiovasc Surg. 1996;111:1047–1053[Abstract/Free Full Text]
6. Burkhoff D, Kohmoto T, DeRosa CM, et al. Initial clinical experience with a holmium:YAG laser: a case study demonstrating increased myocardial perfusion. Whittaker P, Abela G. Transmyocardial Revascularization. New York: Kluwer; 1996. p. 155–162
7. Allen KB, Fudge TL, Selinger SL, et al. Prospective randomized multicenter trial of transmyocardial revascularization versus maximal medical management in patients with class IV angina (abstr). Circulation. 1997;96(Suppl I):I-564
8. Frazier OH, Cooley DA, Kadipasaoglu KA, et al. Myocardial revascularization with laser: preliminary findings. Circulation. 1995;92(Suppl II):II-58–II-65[Free Full Text]
9. ATLANTIC Study InvestigatorsJones JW. : Transmyocardial revascularization improves exercise tolerance: interim results of a randomized trial. Circulation. 1998;98(Suppl I):I-217
10. Kohmoto T, Argenziano M, Yamamoto N, et al. Assessment of transmyocardial perfusion in alligator hearts. Circulation. 1997;95:1585–1591[Abstract/Free Full Text]
11. Hardy RI, James FW, Millard RW, et al. Regional myocardial blood flow and cardiac mechanics in dog hearts with CO2 laser-induced intramyocardial revascularization. Basic Res Cardiol. 1990;85:179–197[CrossRef][Medline]
12. Hardy RI, Bove KE, James FW, et al. A histologic study of laser-induced transmyocardial channels. Lasers Surg Med. 1987;6:563–573[Medline]
13. Kohmoto T, Fisher PE, Gu A, et al. Does blood flow through holmium:YAG transmyocardial laser channels? Ann Thorac Surg. 1996;61:861–868[Abstract/Free Full Text]
14. Kohmoto T, Fisher PE, Gu A, et al. Physiology, histology and 2-week morphology of acute transmyocardial laser channels made with a CO2 laser. Ann Thorac Surg. 1997;63:1275–1283[Abstract/Free Full Text]
15. Fisher PE, Kohmoto T, DeRosa CM, et al. Histologic analysis of transmyocardial laser channels: comparison of CO2 and holmium:YAG lasers. Ann Thorac Surg. 1997;64:466–472[Abstract/Free Full Text]
16. Krabatsch T, Schaper F, Leder C, et al. Histological findings after transmyocardial laser revascularization. J Card Surg. 1996;11:326–331[Medline]
17. Gassler N, Wintzer HO, Stubbe HM, et al. Transmyocardial laser revascularization: histological features in human nonresponder myocardium. Circulation. 1997;95:371–375[Abstract/Free Full Text]
18. Kohmoto T, Fisher PE, Gu A, et al. Physiology of chronic transmyocardial laser channel created with a CO2 laser (abstr). Circulation. 1995;92:I-176
19. Kadipasaoglu KA, Pehlivanoglu S, Conger JL, et al. Long- and short-term effects of transmyocardial laser revascularization in acute myocardial ischemia. Lasers Surg Med. 1997;20:6–14[CrossRef][Medline]
20. Whittaker P, Kloner RA, Przyklenk K. Laser-mediated transmural myocardial channels do not salvage acutely ischemic myocardium. J Am Coll Cardiol. 1993;22:302–309[Abstract]
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481[CrossRef]
22. Pifarre R, Jasuja ML, Lynch RD, et al. Myocardial revascularization by transmyocardial acupuncture: a physiologic impossibility. J Thorac Cardiovasc Surg. 1969;58:424–431[Medline]
23. Oesterle SN, Reifart NJ, Meier B, et al. Initial results of laser-based percutaneous myocardial revascularization for angina pectoris. Am J Cardiol. 1998;82:659–662[CrossRef][Medline]
24. CASS Principal Investigators and their Associates. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery, survival data. Circulation. 1983;68:939–950[Abstract/Free Full Text]
25. European Coronary Surgery Study Group. Long-term results of prospective randomized study of coronary artery bypass surgery in stable angina pectoris. Lancet. 1982;2:1173–1180[Medline]
26. Murphy M, Hultgren H, Detre K, et al. Treatment of chronic stable angina. A preliminary report of survival data of the Randomized Veterans Administration Cooperative Study. N Engl J Med. 1977;297:621–629[Abstract]

This article has been cited by other articles:

				C. R. Bridges, K. A. Horvath, W. C. Nugent, D. M. Shahian, C. K. Haan, R. J. Shemin, K. B. Allen, and F. H. Edwards The Society of Thoracic Surgeons practice guideline series: transmyocardial laser revascularization Ann. Thorac. Surg., April 1, 2004; 77(4): 1494 - 1502. [Abstract] [Full Text] [PDF]

				E. D. Peterson, P. Kaul, R. G. Kaczmarek, B. G. Hammill, P. W. Armstrong, C. R. Bridges, T. B. Ferguson Jr, and Society of Thoracic Surgeons From controlled trials to clinical practice: monitoring transmyocardial revascularization use and outcomes J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1611 - 1616. [Abstract] [Full Text] [PDF]

				M. Saririan and M. J. Eisenberg Myocardial laser revascularization for the treatment of end-stage coronary artery disease J. Am. Coll. Cardiol., January 15, 2003; 41(2): 173 - 183. [Abstract] [Full Text] [PDF]

				M. Ruel, R. A. Kelly, and F. W. Sellke Therapeutic Angiogenesis, Transmyocardial Laser Revascularization, and Cell Therapy Card. Surg. Adult, January 1, 2003; 2(2003): 715 - 750. [Full Text]

				L. Aaberge, K. Rootwelt, S. Blomhoff, K. Saatvedt, M. Abdelnoor, and K. Forfang Continued symptomatic improvement three to five years after transmyocardial revascularization with co2 laser: A late clinical follow-up of the norwegian randomized trial with transmyocardial revascularization J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1588 - 1593. [Abstract] [Full Text] [PDF]

				E.-G. Kraatz, M. Misfeld, B. Jungbluth, and H.-H. Sievers Survival after transmyocardial laser revascularization in relation to nonlasered perfused myocardial zones Ann. Thorac. Surg., February 1, 2001; 71(2): 532 - 536. [Abstract] [Full Text] [PDF]

This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burkhoff, D. Articles by Lansing, A. M. Search for Related Content PubMed PubMed Citation Articles by Burkhoff, D. Articles by Lansing, A. M.